Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Elon Musk’s retreat from DOGE has lifted Tesla’s valuation by $158 billion—but the stock is still 50% off its peak

A TSLA stock rebound led to gains surpassing the current market caps of Amgen or Adobe.

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan

Pharma names whipsawed Wednesday after Trump said he would enact "major" tariffs on drug imports and then backed off his tariffs — for now.

Investors Business Daily

Apple And Meta Get Nixed — But Top Funds Binge On This Stock

While Megacaps Apple and Meta go AWOL, Netflix stock and insurance firms dominate new buys by the best mutual funds.

Investors Business Daily

Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1

Since it joined the Dow industrials on Nov. 7, Nvidia stock is down nearly 30%.

Investors Business Daily

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

inkl

Read news from The Economist, FT, and more,
with one subscription

With 23andMe filing for bankruptcy, what happens to consumers’ genetic data?

With 23andMe filing for bankruptcy, what happens to consumers’ genetic data?

The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its customers into a bit of a privacy tizzy. On March 21, California Attorney General Bob Bonta issued a consumer alert with detailed instructions about how to delete one’s data.

The Conversation

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

IBD Rating Upgrades: Amgen Shows Improved Price Strength

IBD Rating Upgrades: Amgen Shows Improved Price Strength

A Relative Strength Rating upgrade for Amgen shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Generating Improved Relative Strength: Amgen

Stocks Generating Improved Relative Strength: Amgen

Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Amgen stock is an attractive buy on the dip for passive income-focused investors.

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

Investors Business Daily

Dow Jones Falls On Surprise Jobs Data; Google, AMD, Uber Plunge On Earnings

The Dow Jones dropped Wednesday on a strong ADP jobs report. Google, AMD and Uber stock plunged on earnings.

Investors Business Daily

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Get all your
news in one place.

100’s of premium titles.
One news app.

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?

Despite Amgen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Amgen’s Q4 2024 Earnings: What to Expect

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

Investors Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Build a Bulletproof Portfolio with These Three Diversified Dividend Stocks

Learn how diversification, careful screening, and key metrics like payout ratios and yields can help build a strong, income-generating portfolio for the long term.

Selling Covered Calls On The Dogs Of The Dow Stocks

The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones stocks.

Investors Business Daily

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

People

110,007 stories

Robert F. Kennedy Jr

Austan Goolsbee

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

264,571 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play